Altered dipeptidyl peptidase-4 activity during the progression of hyperinsulinemic obesity and islet atrophy in spontaneously late-stage type 2 diabetic rats

American Journal of Physiology - Endocrinology and Metabolism

Volumn 300, Issue 2, 2011, Pages

  Kirino, Yasushi ^a   Sato, Youichi ^a   Kamimoto, Takayuki ^a   Kawazoe, Kazuyoshi ^a   Minakuchi, Kazuo ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Otsuka long evans tokushima fatty rat; Pancreatic islet atrophy

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATROPHY; BODY FAT; BODY WEIGHT; BULIMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET RESTRICTION; DISEASE COURSE; DYSLIPIDEMIA; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; EXERCISE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HYPERINSULINEMIA; HYPOINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; KIDNEY DISEASE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; PANCREAS INSUFFICIENCY; PANCREAS ISLET; PHENOTYPE; POLYURIA; PRIORITY JOURNAL; PROTEINURIA; RAT; SATIETY; WEIGHT REDUCTION;

ANIMALS; AREA UNDER CURVE; ATROPHY; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DISEASE PROGRESSION; FOOD DEPRIVATION; GLUCOSE TOLERANCE TEST; HYPERINSULINISM; IMMUNOHISTOCHEMISTRY; INSULIN; ISLETS OF LANGERHANS; MALE; OBESITY; ORGAN SIZE; PROTEINURIA; RATS; RATS, INBRED OLETF; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SATIATION;

EID: 79251537449     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00319.2010     Document Type: Article

References (22)

1. Chen D, Wang MW. Development and application of rodent models for type 2 diabetes. Diabetes Obes Metab 4: 307-317, 2005. (Pubitemid 40916572)
2. De Meester I, Durinx C, Bal G, Proost P, Struyf S, Goossens F, Augustyns K, Scharpe S. Natural substrates of dipeptidyl peptidase IV. Adv Exp Med Biol 477: 67-87, 2000.
3. Flock G, Baggio LL, Longuet C, Drucker DJ. Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes 56: 3006-3013, 2007.
4. Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 50: 1148-1155, 2007.
5. Hinnen D, Nielsen LL, Waninger A, Kushner P. Incretin mimetics and DPP4 inhibitors: new paradigms for the treatment of type 2 diabetes. J Am Board Fam Med 6: 612-620, 2006.
6. Jackson EK, Mi Z. Sitagliptin augments sympathetic enhancement of the renovascular effects of angiotensin II in genetic hypertension. Hypertension 51: 1637-1642, 2008.
7. Kawano K, Hirashima T, Mori S, Natori T. OLETF (Otsuka Long-Evans Tokushima Fatty) rat: a new NIDDM rat strain. Diabetes Res Clin Pract 24: S317-S320, 1994.
8. Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T. Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 41: 1422-1428, 1992.
9. Kendall DM, Kim D, Maggs D. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of emerging therapies for type 2 diabetes. Diabetes Technol Ther 3: 385-396, 2006.
10. Kirino Y, Kamimoto T, Sato Y, Kawazoe K, Minakuchi K, Nakahori Y. Increased plasma dipeptidyl peptidase IV (DPP4) activity and decreased DPP4 activity of visceral but not subcutaneous adipose tissue in impaired glucose tolerance rats induced by high-fat or high-sucrose diet. Biol Pharm Bull 32: 463-467, 2009.
11. Kirino Y, Sato Y, Kamimoto T, Kawazoe K, Minakuchi K, Nakahori Y. Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using wild-type and DPP4-deficient rats. J Endocrinol 200: 53-61, 2009.
12. Kos K, Backer AR, Jernas M, Harte AL, Clapham JC, O'Hare JP, Carlsson L, Kumar S, McTernan PG. DPP-IV inhibition enhances the antilipolytic action of NPY in human adipose tissue. Diabetes Obes Metab 11: 285-292, 2009.
13. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 85: 9-24, 1999.
14. Mikhail N. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes. Expert Opin Investig Drugs 17: 845-853, 2008.
15. Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H, Fujimoto S, Oku A, Tsuda K, Toyokuni S, Hiai H, Mizunoya W, Fushiki T, Holst JJ, Makino M, Tashita A, Kobara Y, Tsubamoto Y, Jinnouchi T, Jomori T, Seino Y. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 8: 738-742, 2002.
16. Mu J, Petrov A, Eiermann GJ, Woods J, Zhou YP, Li Z, Zycband E, Feng Y, Zhu L, Roy RS, Howard AD, Li C, Thornberry NA, Zhang BB. Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes. Eur J Pharmacol 623: 148-154, 2009.
17. Nielsen LL. Incretin mimetics and DPP4 inhibitors for the treatment of type 2 diabetes. Drug Discov Today 10: 703-710, 2005.
18. Pala L, Mannucci E, Pezzatini A, Ciani S, Sardi J, Raimondi L, Ognibene A, Cappadona A, Vannelli BG, Rotella CM. Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells. Biochem Biophys Res Commun 310: 28-31, 2003. (Pubitemid 37162757)
19. Pospisilik JA, Martin J, Doty T, Ehses JA, Pamir N, Lynn FC, Piteau S, Demuth HU, McIntosh CH, Pederson RA. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 52: 741-750, 2003.
20. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H; Sitagliptin Study 023 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 49: 2564-2571, 2006.
21. Riedel MJ, Lee CW, Kieffer TJ. Engineered glucagon-like peptide-1-producing hepatocytes lower plasma glucose levels in mice. Am J Physiol Endocrinol Metab 296: E936-E944, 2009.
22. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 414: 782-787, 2001.